News Search Results
Jun 23, 2025, 10:15 ET Booming Advanced Wound Care Market Forecasted to Hit $14.87 Billion by 2030 with 4.79% CAGR - Exclusive Report by The Research Insights
dominated the market, accounting for approximately 70.75% of revenue share in 2024.Conclusion: As medical biotechnology, biomaterials, and digital health are
More news about: The Research Insights
Jun 23, 2025, 09:25 ET Origin Agritech to Hold Business Update & First Half of Fiscal Year 2025 Earnings Conference Call on Friday, June 27th at 8 a.m. ET
the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited
Jun 23, 2025, 08:00 ET Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the
More news about: Anixa Biosciences, Inc.
Jun 23, 2025, 07:00 ET Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
Mass., June 23, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported updated results from Part B of the DeFianCe study (
More news about: Leap Therapeutics, Inc.
Jun 23, 2025, 05:00 ET Kanazawa University research: From hydration layers to nanoarchitectures: Water's pivotal role in peptide organization on 2D nanomaterials
sensor devices. Biotechnological applications typically exploit the properties and functionalities of biological molecules. For practical biotechnology devices, it is essential to assemble biomolecules on non-biological substrates. Fortunately, specifically designed biomolecules can achieve structural
More news about: Kanazawa University
Jun 22, 2025, 14:31 ET Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 22, 2025, 12:50 ET RCKT INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
[email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit
More news about: Robbins Geller Rudman & Dowd LLP
Jun 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers - FTRE
global contract research organization ("CRO") that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. The Company claims to have the "scale and expertise to advise, design and deliver [its] customers' programs, projects
More news about: Pomerantz LLP
Jun 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
[Click here for information about joining the class action] PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Pomerantz LLP
Jun 21, 2025, 09:01 ET Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 21, 2025, 09:00 ET MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session
June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of pre-clinical data on DA-1241, a novel G-Protein-Coupled
More news about: MetaVia Inc.
Jun 20, 2025, 16:00 ET Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain:
More news about: Innocan Pharma Corporation
Jun 20, 2025, 16:00 ET Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
/CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain:
More news about: Innocan Pharma Corporation
Jun 20, 2025, 13:15 ET Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Jun 20, 2025, 11:10 ET Faruqi & Faruqi Reminds Fortrea Holdings Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 1, 2025 - FTRE
from buy to hold. Among other things, the Jefferies Report cited perceived weaknesses in the Company's business model as a CRO amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are "not as material as [o]ne [m]ight think," stating
More news about: Faruqi & Faruqi, LLP
Jun 20, 2025, 10:30 ET Natural Carotenoids Market Poised to Reach $3.3 Billion by 2035, Growing at a CAGR of 8.7% from 2025--Exclusive Report by Meticulous Research®
The report highlights significant technological advancements reshaping the industry, including microencapsulation and nano-delivery systems, biotechnology and fermentation-based production methods, and novel extraction technologies. These innovations are addressing traditional challenges such as stability,
More news about: Meticulous Market Research Pvt. Ltd.
Jun 20, 2025, 10:07 ET Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched
More news about: Kalorama Information
Jun 20, 2025, 10:03 ET European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome)
www.leukine.com. ABOUT PARTNER THERAPEUTICSPartner Therapeutics, Inc. (PTx), an integrated biotechnology company, focuses on development and commercialization of late-stage therapeutics to improve health outcomes in treatment of cancer and other serious
More news about: Partner Therapeutics, Inc.
Jun 20, 2025, 09:34 ET PepGen Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against PEPG
(NASDAQ:PEPG) securities between March 7, 2024 and March 3, 2025. PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Robbins LLP
Jun 20, 2025, 09:31 ET Rocket Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against RCKT
between February 7, 2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating
More news about: Robbins LLP
Jun 20, 2025, 08:00 ET LOMOND THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR LONITOCLAX, A SELECTIVE BCL2 INHIBITOR WITH LIMITED IMMUNE SUPPRESSION AND IMPROVED SAFETY COMPARED TO VENETOCLAX AND VENETOCLAX- LIKE MOLECULES
June 20, 2025 /PRNewswire/ -- Lomond Therapeutics Holdings, Inc. ("Lomond Therapeutics"), a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological malignancies,
More news about: Lomond Therapeutics
Jun 20, 2025, 07:30 ET Anixa Biosciences to Host an Investor Webcast on June 26, 2025
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June
More news about: Anixa Biosciences, Inc.
Jun 20, 2025, 02:54 ET MGI Tech Receives CE Mark for DNBSEQ-T1+ Sequencer
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various
More news about: MGI Tech
Jun 20, 2025, 02:21 ET BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Jun 19, 2025, 14:36 ET Biological Safety Cabinets Market to Reach USD 448.4 Million by 2032, Driven by Rising Biosafety Standards and Research Demand
B2)Class III Biological Safety CabinetsBy End-User: Research LaboratoriesPharmaceutical and Biotechnology CompaniesHospitals and Diagnostic CentersAcademic InstitutesBy Application: Drug Discovery
More news about: Credence Research Inc.